Efficacy and safety of сepeginterferon alfa-2b in double treatment regimen (cepeginterferon alfa-2b and ribavirin) of antiviral therapy in patients with chronic hepatitis C genotypes 2 and 3. Experience of real clinical practice
The objective: to analyze the experience of use of cepeginterferonalfa-2b and ribavirin in patients with chronic hepatitis C genotypes 2 and 3 in clinical practice, to evaluate the efficacy, safety and tolerability of this treatment regimen.Materials and methods. From 2013 to 2016 a total of 73 pati...
Main Authors: | A. I. Pavlov, S. M. Kirillov, D. S. Ponomarenko, A. K. Havanshanov, J. V. Fadina, I. V. Bobkova, V. I. Vasenko, G. A. Volodina, T. Yu. Kulikova, Yu. N. Linkova, M. A. Morozova |
---|---|
Format: | Article |
Language: | Russian |
Published: |
Journal Infectology
2016-11-01
|
Series: | Žurnal Infektologii |
Subjects: | |
Online Access: | https://journal.niidi.ru/jofin/article/view/510 |
Similar Items
-
The efficacy and safety of double (cepeginterferon alfa-2b and ribavirin) and triple (simeprevir, cepeginterferon alfa 2b and ribavirin) treatment regimens in chronic hepatitis C patients. The experience of everyday clinical practice
by: N. P. Blokhina, et al.
Published: (2016-07-01) -
Possibilities of using cepeginterferon alpha-2b in double (cepeginterferon alfa-2b and ribavirin) and triple (simeprevir, cepeginterferon alpha-2b, and ribavirin) antiviral therapy regimens for chronic hepatitis C. A review of clinical trials and experience of everyday clinical practice
by: O O Znoyko, et al.
Published: (2016-11-01) -
Early virologic response to сеpeginterferon alfa-2b in combination with ribavirin in treatment of patients with chronic hepatitis C
by: O. O. Znoyko, et al.
Published: (2014-09-01) -
NEW APPROACHES TO THERAPY OF CLASSICAL PH-NEGATIVE MYELOPROLIFERATIVE DISEASES: THE EXPERIENCE OF EARLY THERAPY WITH CEPEGINTERFERON ALPHA-2B
by: A. S. Polyakov, et al.
Published: (2018-05-01) -
Cepeginterferon alfa-2b in the treatment of chronic myeloproliferative diseases
by: A L MELIKYAN, et al.
Published: (2018-07-01)